1,2-二溴-3-硝基苯 | 26429-41-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1,2-二溴-3-硝基苯
• 英文名称: 1,2-dibromo-3-nitrobenzene
• 英文别名: 2,3-dibromonitrobenzene
• CAS: 26429-41-4
• 化学式: C₆H₃Br₂NO₂
• 分子量: 280.903
• InChiKey: LPOQWSWPRAGSBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2904909090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1,2-Dibromo-3-nitrobenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1,2-Dibromo-3-nitrobenzene
CAS number: 26429-41-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H3Br2NO2
Molecular weight: 280.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,2-二溴-3-硝基苯 在 铜 作用下， 以72%的产率得到1-溴-2-(2-溴-6-硝基苯基)-3-硝基苯
  参考文献：
  名称：

  的合成，结构和1,9-双（二甲基氨基）-dibenzothiophene和1,9-双碱度（二甲基氨基）-dibenzoselenophene 1,2）

  摘要：

  在对具有相邻氨基官能团的双（二烷基氨基）芳烃的研究中，合成了标题化合物5和6。通过X射线分析确定它们的结构以及单质子化阳离子5a和6a的结构。的图5和6的强碱度（PK一个= 11.9和11.8±0.1）在5和6中的孤对电子的相互作用和在N⋯ħ⋯Ñ氢键的几何形状方面进行了讨论图5a和6a中。

  DOI：

  10.1016/s0040-4039(00)82074-2
• 作为产物：
  描述：

  二硝基苯胺 在 氢溴酸 、 溶剂黄146 、 sodium nitrite 作用下， 生成 1,2-二溴-3-硝基苯
  参考文献：
  名称：

  Sihlbom, Acta Chemica Scandinavica (1947), 1953, vol. 7, p. 1197,1198,1199,1204

  摘要：

  DOI：

文献信息

• INDOLE CARBOXAMIDE COMPOUNDS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160115126A1

  公开（公告）日：2016-04-28

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR 4 or N; R 1 , R 2 , R 3 , R 4 , and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula (I)的化合物： 或其盐，其中：X为CR 4 或N；R 1 ，R 2 ，R 3 ，R 4 和A在此处定义。还揭示了使用这些化合物作为Bruton's酪氨酸激酶（Btk）抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓各种治疗领域的疾病或疾病的进展方面非常有用，如自身免疫疾病和血管疾病。
• Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor
  作者：Matthew D. Vera、Joseph T. Lundquist、Murty V. Chengalvala、Joshua E. Cottom、Irene B. Feingold、Lloyd M. Garrick、Daniel M. Green、Diane B. Hauze、Charles W. Mann、John F. Mehlmann、John F. Rogers、Linda Shanno、Jay E. Wrobel、Jeffrey C. Pelletier

  DOI：10.1016/j.bmcl.2010.02.099

  日期：2010.4

  orally active GnRH antagonists based on a 4-piperazinylbenzimidazole template, we sought to investigate the properties of heterocyclic isosteres of the benzimidazole template. We report here the synthesis and biological activity of eight novel scaffolds, including imidazopyridines, benzothiazoles and benzoxazoles. The 2-(4-tert-butylphenyl)-8-(piperazin-1-yl)imidazo[1,2-a]pyridine ring system was shown

  促性腺激素释放激素（GnRH）受体的拮抗作用已在生殖组织疾病（例如子宫内膜异位症和前列腺癌）中产生了积极的临床结果。继最近发现基于4-哌嗪基苯并咪唑模板的口服活性GnRH拮抗剂后，我们试图研究苯并咪唑模板的杂环等位体的性质。我们在这里报告了八个新型支架的合成和生物学活性，包括咪唑并吡啶，苯并噻唑和苯并恶唑。2-（4-叔丁基苯基）-8-（哌嗪-1-基）咪唑[1,2- a已显示]吡啶环系统对人和大鼠GnRH受体具有纳摩尔结合力，并在体外具有功能拮抗作用。报告了该系列中其他结构-活性关系以及与基于苯并咪唑的铅分子的药代动力学比较。
• Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
  申请人：Green Michael Daniel

  公开号：US20060264631A1

  公开（公告）日：2006-11-23

  The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

  这项发明涉及促性腺激素释放激素（GnRH，也称为黄体生成素释放激素）受体拮抗剂。
• Efficient synthesis of aryl-substituted carbazoles via tandem double or triple suzuki coupling and cadogan cyclization
  作者：Hyeong Seok Kim、Deuk-young Goo、Sang Kook Woo

  DOI：10.1016/j.tet.2017.01.038

  日期：2017.3

  An efficient one-step method to prepare aryl-substituted carbazoles via tandem double or triple CC bond formations by multiple Suzuki couplings and CN bond formation by Cadogan cyclization has been developed. The developed method employs commercially available or easily preparable polybromonitrobenzenes and arylboronic acids as starting materials, tolerates various functional groups, and provides good

  已经开发了一种有效的一步法，该方法通过多个Suzuki偶联通过串联双或三重C C键形成和通过Cadogan环化形成C N键来制备芳基取代的咔唑。所开发的方法采用可商购或易于制备的聚溴硝基苯和芳基硼酸作为起始原料，可耐受各种官能团，并提供良好的收率。
• [EN] PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PYRIMIDINE ET COMPOSÉS DE PYRIMIDO INDOLE ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：UNIV HOLY GHOST DUQUESNE

  公开号：WO2016022890A1

  公开（公告）日：2016-02-11

  The present invention discloses substituted pyrimidine and pyrimido indole compounds and optionally pharmaceutically acceptable salts, hydrates or solvates thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt, hydrate, or solvate thereof.

  本发明公开了取代嘧啶和嘧啶并吲哚化合物以及可选择的药用盐、水合物或溶剂化合物。一种治疗患有癌症或疾病的患者的方法包括向患者投予化合物或其药用盐、水合物或溶剂化合物的有效量。